Shareholders Equity: The sum of preferred and common equity items.
Rhythm Pharmaceuticals, Inc. (RYTM) had Shareholders Equity of $201.54M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$92.13M |
|
$-42.35M |
|
$12.17M |
|
$79.96M |
|
$131.40M |
|
$-39.27M |
|
$-1.49M |
|
$-40.76M |
|
$-40.76M |
|
$-41.37M |
|
$-41.37M |
|
$-41.37M |
|
$-41.37M |
|
$-39.27M |
|
$-39.02M |
|
69.05M |
|
69.05M |
|
$-0.61 |
|
$-0.61 |
|
| Balance Sheet Financials | |
$419.36M |
|
$0.57M |
|
$23.77M |
|
$443.13M |
|
$150.89M |
|
-- |
|
$90.70M |
|
$241.59M |
|
$87.97M |
|
$184.87M |
|
|
Shareholders Equity |
$201.54M |
69.31M |
|
| Cash Flow Statement Financials | |
$-56.40M |
|
$54.96M |
|
$-12.81M |
|
$54.82M |
|
$41.26M |
|
$-13.56M |
|
$74.18M |
|
-- |
|
$-1.46M |
|
| Fundamental Metrics & Ratios | |
2.78 |
|
-- |
|
-- |
|
-- |
|
-- |
|
86.79% |
|
-42.63% |
|
-42.63% |
|
-- |
|
-44.24% |
|
-45.97% |
|
$-56.90M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
0.39 |
|
2.35 |
|
38.22 |
|
-47.03% |
|
-22.38% |
|
-9.34% |
|
-20.53% |
|
$2.91 |
|
$-0.82 |
|
$-0.82 |
|